Trial Profile

Biomarker analysis of WJOG6410L/IMPACT: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutation

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jul 2023 New trial record
06 Jun 2023 Results of biomarker analysis (n=202) assessing the efficacy of adjuvant osimertinib and the risk of postoperative recurrence in completely resected NSCLC harboring EGFR mutations, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com